HSCS
HeartSciences Inc.2.3100
-0.1600-6.48%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.34MP/E (TTM)
-Basic EPS (TTM)
-6.56Dividend Yield
0%Recent Filings
8-K
Secures $3M note
HeartSciences secured $3M in gross proceeds via an unsecured promissory note to Streeterville Capital on January 13, 2026, with a $3.605M face value including $600K OID. The note carries 12% interest, matures in 18 months, and allows monthly redemptions up to $405K starting six months in—yet balance balloons 5% if not cut by $1.25M in year one. Investor-friendly covenants curb further debt.
8-K
Board approves director indemnification
HeartSciences' board approved a form of Indemnification Agreement on December 15, 2025, for directors and executive officers, promising indemnity and expense advances to Texas law's fullest extent, plus D&O insurance coverage. This standard governance move aims to attract talent amid litigation risks and insurance hurdles. Directors get robust protection. No financial terms disclosed.
8-K
Q2 results: no revenue, FDA submission
HeartSciences reported no meaningful revenue for FQ2 2026 ended October 31, with $2.0 million cash and $4.2 million shareholders' equity as of then. MyoVista Insights gained early adopter validation and commercial talks since May launch; it's MDDS-exempt for fast rollout. Key milestone: FDA 510(k) submission for MyoVista wavECG device. Cash burn persists.
10-Q
Q2 FY2026 results
HeartSciences posted Q2 FY2026 revenue of $2.4k, up from zero y/y, with gross margin at $1.4k; six-month totals hit $4.3k versus nothing last year. Operating loss narrowed to $2.1M from $2.0M y/y while net loss widened to $2.4M from $2.1M, driven by $280k interest expense versus $118k (higher Streeterville Note amortization). Cash climbed to $2.0M on $6.7M Series D proceeds, fully retiring Streeterville debt; FRV $500k note matures 2026 at 12%. Equity jumped to $4.2M. Cash burn persists. Nasdaq compliance holds. FDA delays loom.
8-K
Equity plan expanded, awards granted
HeartSciences amended its 2023 Equity Incentive Plan on November 28, 2025, boosting the share pool to 1,250,000 plus an annual evergreen provision up to 25% of outstanding stock, pending shareholder approval at the next annual meeting. The board granted 70,000 restricted shares to CEO Andrew Simpson, 45,000 RSUs to COO Mark Hilz, 15,000 RSUs to CFO Danielle Watson, and 15,000 RSUs each to non-employee directors, vesting over 2-3 years or fully on change of control or $250,000 quarterly revenue. Awards hinge on shareholder nod. Retention locked in.
BEAT
Heartbeam, Inc.
3.44+0.81
BSX
Boston Scientific Corporation
92.95+0.76
CBLL
CeriBell, Inc.
21.99+0.09
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.60+0.00
EW
Edwards Lifesciences Corporatio
85.32+1.94
HTFL
Heartflow, Inc.
26.47+0.84
HWAIF
HealWELL AI Inc.
0.64+0.00
NVNO
enVVeno Medical Corporation
0.32+0.01
PMI
Picard Medical, Inc.
2.30-0.13
VTAK
Catheter Precision, Inc.
2.19-0.04